Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity in Adults of Revaccination With Adacel Vaccine 10 Years After a Previous Dose.

Trial Profile

Safety and Immunogenicity in Adults of Revaccination With Adacel Vaccine 10 Years After a Previous Dose.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP vaccine (Primary) ; Diphtheria-tetanus vaccine
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi; Sanofi Pasteur
  • Most Recent Events

    • 14 Jan 2019 According to a Food and Drug Administration media release, Sanofi Pasteur has provided the results of the study to the CDC's Advisory Committee on Immunization Practices for their consideration in future recommendations.
    • 14 Jan 2019 According to a Food and Drug Administration media release, results from the study have been published in the Journal of the Pediatric Infectious Diseases Society in February 2018.
    • 14 Jan 2019 According to a Food and Drug Administration media release, based on the data from the study, The U.S. Food and Drug Administration has approved the expanded use of Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top